Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
- Strategic move to maintain Nasdaq listing compliance
- Consolidation of shares may improve trading dynamics
- No loss of value for fractional shares as they will be rounded up
- Significant share consolidation ratio of 25:1 indicates substantial previous stock price decline
- Reverse splits are often viewed negatively by the market
- May indicate underlying financial or operational challenges
Insights
Shuttle Pharma's 1-for-25 reverse split aims to maintain Nasdaq listing compliance, signaling financial challenges despite strategic positioning.
Shuttle Pharmaceuticals has announced a 1-for-25 reverse stock split effective June 16, 2025, reducing outstanding shares from 26,210,037 to approximately 1,048,401. This drastic consolidation typically indicates underlying financial distress, as companies generally resort to reverse splits when share prices fall below exchange minimums. The press release explicitly confirms this is to maintain compliance with Nasdaq's continued listing requirements, suggesting the stock has likely been trading below the $1 minimum bid price required by Nasdaq.
The timing is strategic, occurring before market open on June 16 to minimize trading disruption. While reverse splits don't inherently change company value (market capitalization theoretically remains unchanged), they often face negative market reception as they signal financial struggles and can increase share price volatility. Importantly, the split applies to all outstanding securities including RSUs and warrants, maintaining proportional ownership stakes.
For investors, reverse splits historically correlate with poor short-term performance, as they reflect fundamental challenges rather than address them. Shuttle's positioning of this as "strengthening the Company's long-term capital structure" attempts to frame it positively, but doesn't change the underlying reality that this is a defensive maneuver to prevent delisting. Without accompanying operational improvements or capital infusion, reverse splits alone rarely solve the underlying issues that necessitated them in the first place.
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m., Eastern Time. The Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existing symbol “SHPH” and will begin trading on a split-adjusted basis when the market opens on June 16, 2025. The new CUSIP number for the common stock following the reverse stock split will be 825693401.
At the effective time of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 26,210,037 shares to approximately 1,048,401 shares, without giving effect to rounding. The split will also apply to Company common stock issuable upon the exercise of the Company's outstanding RSU grants and warrants. No fractional shares will be issued; instead, any fractional entitlements will be rounded up to the next highest whole number at the participant level.
The reverse stock split is part of Shuttle’s strategic plan to maintain compliance with Nasdaq’s continued listing requirements, while also strengthening the Company’s long-term capital structure.
About Shuttle Pharmaceuticals
Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
shph@lythampartners.com
FAQ
What is the reverse stock split ratio for Shuttle Pharmaceuticals (SHPH)?
When will SHPH reverse stock split take effect?
How many shares will Shuttle Pharmaceuticals have after the reverse split?
What happens to fractional shares in the SHPH reverse split?
Why is Shuttle Pharmaceuticals (SHPH) doing a reverse stock split?
